ABSTRACT

Provided herein is a pharmaceutical combination comprising SFRP2 antagonist and an PD-1 antibody antagonist. The invention also provides a method for the treatment of cancer, comprising the administration of a therapeutically effective amounts of a SFRP2 antagonist and a PD-1 antagonist to a patient in need thereof.

[No figure to accompany]